Form 4 for MRK Merck & Co.
Accepted 2023-05-03 00:00:00 ET · period of report 2023-05-01 · accession 0001127602-23-014278 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-03 | 2023-05-02 | MRK | Williams David Michael | EVP, Chief Info, Digital Off | S - Sale+OE | $116.82 | -7,509 | 11.1K | -40% | -$877.2K |
| DM | 2023-05-03 | 2023-05-01+ | MRK | Williams David Michael | EVP, Chief Info, Digital Off | M - OptEx | $61.23 | +6,612 | 12.7K | +108% | +$404.8K |
| D | 2023-05-03 | 2023-05-01 | MRK | Williams David Michael | EVP, Chief Info, Digital Off | F - Tax | $115.47 | -198 | 12.5K | -2% | -$22.9K |
| DM | 2023-05-03 | 2023-05-01+ | MRK | Williams David Michael | EVP, Chief Info, Digital Off | M - OptEx | $0.00 | -6,612 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-02 | S | D | 7,509 | $116.82 | 11,058.96 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.7200 to $116.8800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| 2 | Common | Common Stock | 2023-05-02 | M | A | 6,035 | $56.04 | 18,567.96 | D | — | — | |
| 3 | Common | Common Stock | 2023-05-01 | F | D | 198 | $115.47 | 12,532.96 | D | — | — | |
| 4 | Common | Common Stock | 2023-05-01 | M | A | 577 | $115.47 | 12,730.96 | D | — | — | (F1) Holdings include shares acquired in dividend reinvestment transactions. |
| 5 | Derivative | Restricted Stock Unit | 2023-05-01 | M | D | 577 | $0.00 | 0 | D | — · 2021-05-01 to 2023-05-01 | 577 Common Stock | (F3) Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. (F4) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. |
| 6 | Derivative | Stock Option (Right to Buy) | 2023-05-02 | M | D | 6,035 | $0.00 | 0 | D | $56.04 · 2019-05-04 to 2028-05-03 | 6,035 Common Stock | (F5) Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. (F6) The option became exercisable in equal installments on 5/4/2019, 5/4/2020, and 5/4/2021. |